Navigation Links
Obesity-linked high blood volumes render PSA prostate cancer test less effective, study suggests
Date:11/20/2007

The extra blood volume produced in the obese may so dilute levels of a telltale protein produced by prostates that the popular PSA test may be essentially useless for diagnosing prostate cancer in men carrying extra pounds, a new study in The Journal of the American Medical Association suggests.

The new research, combining data from more than 13,000 prostate cancer patients at The Johns Hopkins Hospital and elsewhere, could eventually affect the reliability of scores of other blood tests for cancer and other diseases in obese people, or at least alter the way those tests are analyzed, investigators say.

The predictive value of the PSA test depends on accurate readings of a protein, (P)rostate (S)pecific (A)ntigen continually pumped out by the prostate. When the prostate is enlarged - due to cancer or other disorders - the concentration of PSA in the bloodstream can increase, signaling the possible presence of a tumor. Physicians thus commonly regard increased PSA values as a first marker to diagnose prostate cancer, to be followed by other diagnostic tests such as physical exams and ultrasound.

Complicating the picture further, the researchers note, that both physical exams and imaging studies are more difficult in obese men.

Although recent studies have shown that PSA concentrations can be lower than expected in obese men with prostate cancer, the current research was designed to determine which of two dueling hypotheses explained this, notes Alan Partin, M.D., chief of the Department of Urology at Johns Hopkins Brady Urological Institute.

One idea was based on the possibility that obese men make less PSA because they tend to have less testosterone, the sex hormone that prompts PSA production. The other attributed the phenomenon to the increased amount of blood that obese men produce to support their size, which has the effect of thinning out the concentration of PSA.

Partin and Stephen Freedland, M.D., Partins former postdoctoral fellow who is now an assistant professor at Duke University, investigated both ideas by assessing how much total PSA obese and normal-weight men have.

Using records of patients treated for prostate cancer between 1988 and 2006 at The Johns Hopkins Hospital, Duke University and various Veterans Affairs hospitals, Partin, Freedland and their colleagues compiled information on PSA concentration and body mass index (BMI), a ratio of body weight to height that generally indicates whether someone is underweight, normal weight or overweight.

Using a standard calculation, the researchers used BMIs to estimate the amount of blood circulating in each patients body. A different calculation used this blood volume, along with PSA concentrations, to estimate the total amount of PSA each patient had.

As expected, PSA concentrations were typically lower in the obese patients than in the normal-weight ones, although the total amount of PSA was about the same in both groups of patients.

Its clear to us that excess blood had diluted PSA concentrations in that group, says Partin.

Freedland says a variety of new tests currently in development for cancer and other diseases rely on the concentrations of disease markers similar to PSA circulating in the blood. For these other tests just starting down the development pipeline, he says, we need to think about the actual total amount of a biological marker rather than concentration.


'/>"/>

Contact: Christen Brownlee
cbrownlee@jhmi.edu
410-955-7832
Johns Hopkins Medical Institutions
Source:Eurekalert

Related medicine news :

1. Specific antagonism lowers blood pressure
2. Restricting Blood Flow May Help Heart Bypass Patients
3. FDA Updates Prescription Guidelines for Blood Thinner
4. Doctors Often Miss High Blood Pressure in Kids
5. Back to School Means Return of School Blood Drives
6. Blood-flow detector software show promise in preventing brain damage
7. FDA Approves New Roche West Nile Virus Blood Screening Test
8. Australian-led international study shows blood pressure drugs cut death rate in type 2 diabetes
9. Laser blasts viruses in blood
10. Study Demonstrates Marteks Algal DHA Oil Improves Blood Triglyceride Lipid Levels
11. LifeMasters Provides Tips for Maintaining a Healthy Blood Cholesterol Level
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/22/2017)... ... April 22, 2017 , ... The San Juan Capistrano summer camp team ... report outlining the need for summer camps to provide physical activities for all campers. To ... Activity In Summer Camps , With an increase in specialty camps that focus on what ...
(Date:4/21/2017)... , ... April 21, 2017 , ... ... Christopher Salas-Wright finds that youth violence is declining—and at noteworthy rates. Between 2002 ... proportion of young people involved in violence in the United States. The study, ...
(Date:4/21/2017)... ... April 21, 2017 , ... Young Asset Protection, an insurance ... throughout the greater Pittsburgh metropolitan region, is joining forces with the local chapter ... differently-abled children. , Variety the Children’s Charity is a national organization dedicated to ...
(Date:4/21/2017)... ... April 21, 2017 , ... The VIA ... Record (AOR) for Theravent, Inc. , the makers of a revolutionary new ... Consumer Healthcare, is now working to expand distribution in anticipation of a national ...
(Date:4/21/2017)... ... April 21, 2017 , ... Alive for Wellness is a group ... mental health struggles. The Alive team uses advanced behavioral sciences treatment modalities to ... with a mental health struggle is based on 10 modalities of treatment ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... , April 19, 2017  IRIDEX Corporation (Nasdaq: ... financial results for the first quarter 2017 after the ... Company,s management team will host a corresponding conference call ... Investors interested in listening to the conference ... domestic callers or (703) 326-3030 for international callers, using ...
(Date:4/19/2017)... April 19, 2017  Sorrento Therapeutics, Inc. (NASDAQ: ... biopharmaceutical company developing new treatments for cancer and ... of its previously announced underwritten public offering of ... public offering price of $2.00 per share, before ... expenses payable by Sorrento.  The net proceeds to ...
(Date:4/18/2017)... , April 18, 2017  Cardinal Health (NYSE: ... 1 fiscal 2017 earnings per share (EPS) guidance ... 2019.  This is in conjunction with this morning,s announcement ... Vein Thrombosis and Nutritional Insufficiency businesses. Cardinal ... continuing operations will be at the bottom of its ...
Breaking Medicine Technology: